Abstract
We describe a patient with probable dementia with Lewy bodies (DLB) whose Parkinsonism worsened after administration of rivastigmine within the therapeutic dose range. Some extrapyramidal signs (EPS) then reversed to pre-treatment level after rivastigmine dose reduction. We draw attention to the need of EPS monitoring during titration of cholinesterase inhibitors in patients with DLB. This is the first report to our knowledge of iatrogenic worsening of Parkinsonism which was successfully managed by dose reduction.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylcholine / metabolism*
-
Aged
-
Cholinesterase Inhibitors / administration & dosage*
-
Cholinesterase Inhibitors / adverse effects
-
Disease Progression
-
Humans
-
Lewy Body Disease / complications
-
Male
-
Parkinsonian Disorders / drug therapy*
-
Parkinsonian Disorders / etiology
-
Phenylcarbamates / administration & dosage*
-
Phenylcarbamates / adverse effects
-
Rivastigmine
-
Time Factors
Substances
-
Cholinesterase Inhibitors
-
Phenylcarbamates
-
Acetylcholine
-
Rivastigmine